Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.80.

Several research analysts have weighed in on the stock. Lake Street Capital assumed coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price target on the stock. Zacks Research lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. HC Wainwright reaffirmed a “buy” rating and issued a $1.00 target price (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Finally, D. Boral Capital cut their price target on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, January 22nd.

Institutional Investors Weigh In On Plus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PSTV. Susquehanna International Group LLP purchased a new position in Plus Therapeutics during the third quarter valued at approximately $46,000. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics during the 2nd quarter valued at $41,000. Scientech Research LLC purchased a new position in shares of Plus Therapeutics during the 3rd quarter valued at $100,000. Finally, Altium Capital Management LLC purchased a new position in shares of Plus Therapeutics during the 3rd quarter valued at $628,000. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Stock Up 11.1%

Shares of NASDAQ:PSTV opened at $0.26 on Monday. The stock has a market capitalization of $36.10 million, a PE ratio of -0.14 and a beta of 0.89. The firm’s 50 day moving average price is $0.47 and its 200-day moving average price is $0.53. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.